Patents Assigned to Secretary, Department of Health & Human Services
-
Publication number: 20240002445Abstract: Disclosed is a class of knotted cyclic peptides. Related pharmaceutical compositions and methods of using the peptides and methods of synthesizing the peptides are also disclosed.Type: ApplicationFiled: November 17, 2021Publication date: January 4, 2024Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Barry R. O'Keefe, Lauren R. Haugh Krumpe, Yves Pommier, Christophe R. Marchand, Ingrid C. Schroeder, K. Johan Rosengren, Brice A.P. Wilson
-
Publication number: 20240003870Abstract: A method of selecting T cells with improved anti-cancer activity, the method including: a) quantifying glucose transporter 1 (GLUT1) expression level at the cell surface of a population of T cells by using a GLUT1 ligand, b) selecting T cells having a low GLUT1 expression level, wherein the T cells having a low GLUT1 expression level have improved anti-cancer activity. Also, a population of T cells with improved anti-cancer activity for use in the treatment of cancer, to the use of a GLUT1 ligand for selecting T cells with improved anti-cancer activity, and to the use of GLUT1 as a biomarker of the anti-cancer therapeutic efficacy of T cells.Type: ApplicationFiled: November 5, 2021Publication date: January 4, 2024Applicants: METAFORA BIOSYSTEMS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, THE UNITED STATES OF AMERICA ,ASREPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICEInventors: Naomi TAYLOR, Marie Charlotte Chantal POUZOLLES, Valérie DARDALHON, Vincent PETIT
-
Patent number: 11860258Abstract: Methods, computing devices, and MRI systems that reduce artifacts produced by Maxwell gradient terms in TSE imaging using non-rectilinear trajectories are disclosed. With this technology, a RF excitation pulse is generated to produce transverse magnetization that generates a NMR signal and a series of RF refocusing pulses to produce a corresponding series of NMR spin-echo signals. An original encoding gradient waveform comprising a non-rectilinear trajectory is modified by adjusting a portion of the original encoding gradient waveform or introducing a zero zeroth-moment waveform segment at end(s) of the original encoding gradient waveform. During an interval adjacent to each of the series of RF refocusing pulses a first gradient pulse is generated. At least one of the first gradient pulses is generated according to the modified gradient waveform. An image is constructed from generated digitized samples of the NMR spin-echo signals obtained.Type: GrantFiled: April 28, 2022Date of Patent: January 2, 2024Assignees: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, SIEMENS HEALTHCARE GMBH, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESInventors: John P. Mugler, III, Craig H. Meyer, Adrienne Campbell, Rajiv Ramasawmy, Josef Pfeuffer, Zhixing Wang, Xue Feng
-
Publication number: 20230414381Abstract: Disclosed are powered gait assistance systems that include a controller, sensors, and a torque applicator (motor, spring, etc.) coupled to a patient's hips, thighs, knee, lower leg, ankle, and/or foot and operable to apply assistive torque to the patient's leg joint(s) to assist the patient's volitional joint actuating muscle output during selected stages of the patient's gait cycle, such that the applied torque improves the patient's leg posture, muscle output, range of motion, and/or other parameters over the gait cycle. The sensors can include a torque sensor that measures torque applied, one or more joint angle sensors, a ground contact sensor that measures ground contact of the patient's foot, and/or other sensors. The controller can determine what stage of the patient's gait cycle the patient's leg is in based on sensor signals and cause the torque applicator to apply corresponding torque to the joint(s) based on the gait cycle stage, sensor inputs, and known patient characteristics.Type: ApplicationFiled: September 7, 2023Publication date: December 28, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Thomas Bulea, Zachary Lerner, Diane Damiano, Andrew Gravunder
-
Patent number: 11850236Abstract: The present invention concerns the use of compounds and compositions for the treatment or prevention of Flavivirus infections, such as dengue virus infections and Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as dengue virus and Zika virus infection, by administering a compound or composition of the invention, to a subject in need thereof; methods for inhibiting Flavivirus infections, such as dengue virus and Zika virus infections, in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits useful for treating or preventing Flavivirus infections, such as dengue virus and Zika virus infections.Type: GrantFiled: June 28, 2022Date of Patent: December 26, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Florida State University Research Foundation, Inc., The Trustees of the University of PennsylvaniaInventors: Hengli Tang, Emily M. Lee, Wei Zheng, Ruili Huang, Miao Xu, Wenwei Huang, Khalida Shamim, Guoli Ming, Hongjun Song
-
Patent number: 11851498Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of (a) cancer or (b) tumor vasculature in a mammal and methods of (a) treating or preventing cancer or (b) reducing tumor vasculature in a mammal are also disclosed.Type: GrantFiled: March 9, 2020Date of Patent: December 26, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, BioMed Valley Discoveries, Inc.Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Bradley St. Croix, Steven Seaman, Saurabh Saha, Xiaoyan Michelle Zhang, Gary A. DeCrescenzo, Dean Welsch
-
Publication number: 20230405027Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.Type: ApplicationFiled: May 19, 2023Publication date: December 21, 2023Applicant: THE U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Walid Heneine, Thomas M. Folks, Robert Janssen, Ronald A. Otten, Jose Gerardo Garcia Lerma
-
Publication number: 20230406953Abstract: Nucleic acid constructs encoding a chimeric antigen receptor (CAR) and a truncated human epidermal growth factor receptor (huEGFRt) are described. The encoded CARs include a tumor antigen-specific monoclonal antibody, such as a glypican-3 (GPC3)-specific, a GPC2-specific or a mesothelin-specific monoclonal antibody, fused to a CD8? hinge region, a CD8? transmembrane region, a 4-1BB co-stimulatory domain and a CD3? signaling domain. Isolated host cells, such as isolated T cells that co-express the disclosed CARs and huEGFRt are also described. T cells transduced with the disclosed CAR constructs can be used for cancer immunotherapy.Type: ApplicationFiled: July 26, 2023Publication date: December 21, 2023Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Nan Li, Dan Li
-
Patent number: 11846690Abstract: Multi-dimensional spectra associated with a specimen are reconstructed using lower dimensional spectra as constraints. For example, a two-dimensional spectrum associated with diffusivity and spin-lattice relaxation time is obtained using one-dimensional spectra associated with diffusivity and spin-lattice relaxation time, respectively, as constraints. Data for a full two dimensional spectrum are not acquired, leading to significantly reduced data acquisition times.Type: GrantFiled: July 13, 2022Date of Patent: December 19, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter J. Basser, Dan H. Benjamini
-
Patent number: 11845778Abstract: Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.Type: GrantFiled: July 16, 2021Date of Patent: December 19, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Institute for Research in BiomedicineInventors: Baoshan Zhang, Guillaume Stewart-Jones, John Mascola, Kai Xu, Gwo-Yu Chuang, Li Ou, Peter Kwong, Yaroslav Tsybovsky, Wing-Pui Kong, Aliaksandr Druz, Davide Corti, Antonio Lanzavecchia
-
Patent number: 11844769Abstract: The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.Type: GrantFiled: June 2, 2021Date of Patent: December 19, 2023Assignees: MESHABERASE, LLC, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Benjamin Rubin, Mark Gilbert, Jinkyu Jung
-
Patent number: 11840561Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.Type: GrantFiled: December 3, 2021Date of Patent: December 12, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
-
Publication number: 20230390313Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self-replicating after infecting a primate host.Type: ApplicationFiled: June 6, 2023Publication date: December 7, 2023Applicant: THE U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Walid Heneine, Thomas M. Folks, Robert Janssen, Ronald A. Otten, Jose Gerardo Garcia Lerma
-
Publication number: 20230391852Abstract: Polypeptides that specifically bind the spike (S) protein of human coronavirus, selected from six camel VHH single domain antibody phage display libraries, are described. The S protein-specific polypeptides disrupt binding of the SARS-CoV-2 and/or SARS-CoV S protein to the cellular receptor ACE2, which is important for neutralization of the virus. Use of the S protein-specific polypeptides for the diagnosis and treatment of SARS-CoV-2 and/or SARS-CoV is described.Type: ApplicationFiled: October 26, 2021Publication date: December 7, 2023Applicant: The U.S.A., as Represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Jessica Diana Hong
-
Publication number: 20230390322Abstract: Methods are disclosed for treating a subject with a cobalamin C (cblC) deficiency. These methods include selecting a human subject with the cblC deficiency; and administering about 5 mg to about 10 grams of methylcobalamin (MeCbl) daily to the human subject. Methods also are disclosed for treating a fetus with a cobalamin C (cblC) deficiency. The methods include selecting a female human subject pregnant with the fetus that has the cblC deficiency; and administering about 5 mg to about 10 grams of MeCbl daily to the female human subject, in order to treat the cblC deficiency in the fetus. Optionally, OHCbl can be administered to the subject.Type: ApplicationFiled: October 12, 2021Publication date: December 7, 2023Applicant: THE U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Charles P. Venditti, Jennifer Lyn Sloan, Eirini Manoli
-
Patent number: 11835611Abstract: Isotropic generalized diffusion tensor imaging methods and apparatus are configured to obtain signal attenuations using selected sets of applied magnetic field gradient directions whose averages produce mean apparent diffusion constants (mADCs) over a wide range of b-values, associated with higher order diffusion tensors (HOT). These sets are selected based on analytical descriptions of isotropic HOTs and the associated averaged signal attenuations are combined to produce mADCs, or probability density functions of intravoxel mADC distributions. Estimates of biologically-specific rotation-invariant parameters for quantifying tissue water mobilities or other tissue characteristics can be obtained such as Traces of HOTs associated with diffusion and mean t-kurtosis.Type: GrantFiled: April 6, 2018Date of Patent: December 5, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter J. Basser, Alexandru V. Avram
-
Patent number: 11833199Abstract: Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.Type: GrantFiled: November 16, 2021Date of Patent: December 5, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Surender Khurana
-
Patent number: 11834509Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for TSLPR, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of a proliferative disorder, e.g., cancer, in a mammal and methods of treating or preventing a proliferative disorder, e.g., cancer, in a mammal are also disclosed.Type: GrantFiled: April 28, 2020Date of Patent: December 5, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Haiying Qin, Terry J. Fry
-
Publication number: 20230382857Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary system are disclosed. Certain heptamethine cyanines exhibit biliary system specificity and methods for in vivo visualization of a biliary system of a subject are provided. The methods may be for diagnostic purposes and/or for visualization of biliary systems during surgery.Type: ApplicationFiled: July 25, 2023Publication date: November 30, 2023Applicants: CHILDREN'S NATIONAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Martin John SCHNERMANN, Peter C.W. KIM, Jaepyeong CHA, Roger Rauhauser NANI
-
Publication number: 20230383278Abstract: The present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV) and methods of using such vectors and viruses in gene therapy for treating methylmalonic acidemia in patients with methylmalonyl-coA mutase (MVMUT) deficiency. Also provided are pharmaceutical compositions comprising recombinant adeno-associated virus (rAAV) and a pharmaceutically acceptable carrier or excipient.Type: ApplicationFiled: September 16, 2021Publication date: November 30, 2023Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Charles P. Venditti, Randy Chandler